**Core tip:** Recently, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been suggested as important inflammatory markers and potential predictors of long-term outcomes in patients with colorectal cancer (CRC). However, the direct impact of NLR and PLR on long-term outcomes in patients with CRC remains inconclusive. In this study, we identified that high NLR and high PLR are useful independent prognostic factors to predict poor long-term outcomes in patients with stage III and IV CRC. And we propose that initial assessment of NLR and PLR in newly diagnosed stage III and IV CRC patients is important for predicting long-term outcomes.

INTRODUCTION
============

Colorectal cancer (CRC) is the third most common tumor in men and the second in women worldwide\[[@B1]\]. According to the database of GLOBOCAN 2012, 1.4 million new CRC cases and 694000 CRC deaths occurred in 2012 worldwide\[[@B2]\]. In Eastern Asia, CRC occurs in more than 37.0 per 100000 individuals per year and accounts for approximately 207700 annual deaths\[[@B2]\]. Although the 5-year relative survival rate of CRC has been increasing over the past few decades, CRC is still the third leading cause of cancer-related death in the world and the median overall survival of patients with metastatic CRC is less than 30 mo\[[@B3],[@B4]\]. Identification of prognostic markers is an important step for assessing clinical outcome in CRC treatment. In previous studies, tumor stage, histologic grade, number of resected lymph nodes, lymphatic, venous or peri-neural invasion, and carcinoembryonic antigen (CEA) level have been demonstrated as prognostic factors\[[@B5]-[@B8]\]. Recently, a large number of studies have suggested useful biomarkers for predicting clinical outcomes in CRC, however high costs and lack of standardization limit their application in routine clinical practice\[[@B9],[@B10]\].

Previous reports have shown that the inflammatory response increases the risk of developing many types of cancer\[[@B11],[@B12]\]. Some transcription factors including NF-kB and STAT3 (signal transducer and activator of transcription 3) and several inflammatory cytokines (such as IL-1β, IL-6, IL-23, and TNF-α) are involved in cancer-related inflammation. Therefore, it has been suggested that the inhibition of these transcription factors and cytokines could decrease the incidence and spread of cancer\[[@B11]\]. In particular, non-steroidal anti-inflammatory drugs reduce the risk of developing CRC and the mortality of CRC\[[@B13]-[@B15]\]. At this time, it is widely accepted that the inflammatory response has a crucial role in the pathogenesis and progression of cancer. Among the various inflammatory markers, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been shown to influence clinical outcomes in various cancers\[[@B16]-[@B19]\]. NLR and PLR can be easily calculated as the neutrophil count or platelet count divided by the lymphocyte count. Because neutrophil count, platelet count, and lymphocyte count are routinely evaluated, the assessment of NLR and PLR could be routinely used without additional cost in clinical practice. An elevated neutrophil count promotes tumor growth and metastasis by remodeling the extracellular matrix, releasing reactive oxygen species, and suppressing lymphocyte activity\[[@B20]\]. In addition, the presence of tumor cells affects platelets and causes cancer-induced thrombosis\[[@B21]\]. As a result of this activation, platelets release a number of growth factors which support tumor growth, angiogenesis, and metastasis\[[@B22]\]. Recently, NLR and PLR have been suggested as important inflammatory markers and potential predictors of long-term outcomes in patients with CRC\[[@B23]-[@B26]\]. However, because of the diversity in study designs, heterogeneous enrolled patient groups, and different cutoff values, the direct impact of NLR and PLR on long-term outcomes in patients with CRC remains inconclusive. In this study, we aimed to identify the prognostic value of the NLR and PLR in patients with CRC.

MATERIALS AND METHODS
=====================

Patients
--------

Between April 1996 and December 2010, the medical records from patients diagnosed with CRC at Kosin University Gospel Hospital (Busan, Korea) were retrospectively reviewed. Patients who were histologically confirmed to have CRC were included. Patients whose medical records did not include complete blood count, and clinicopathological and follow-up data were excluded. Detailed clinical data including patient age, gender, tumor location, histopathology, tumor stage, and use of chemotherapy were collected. This study was approved by the Institutional Review Board of Kosin University Gospel Hospital (KUGH 2016-06-033).

Assessment of NLR and PLR
-------------------------

All blood samples were taken at the time of admission for initial diagnosis and the neutrophil, platelet, and lymphocyte counts identified in these blood samples were used to calculate the NLR and PLR. NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count, and PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count. Cutoff values, sensitivity, and specificity of the NLR and PLR were evaluated using receiver operating characteristic (ROC) curves.

Patient follow-up and statistical analysis
------------------------------------------

The overall survival (OS) was measured from the date of CRC diagnosis to the date of death or final follow-up. The disease free survival (DFS) was measured from the date of CRC diagnosis to the date of recurrence or final follow-up. The recurrence of CRC was diagnosed on radiological and endoscopic histopathological data. Student\'s *t*-test and *χ*^2^ test were performed for continuous and categorical variables, as appropriate. ROC curves were used to differentiate the ability of the NLR and PLR to predict long-term outcomes in patients with CRC. Kaplan-Meier curves were used to construct survival curves based on cumulative incidences and compared using the Breslow test. Cox proportional hazards regression model was used to assess factors affecting the OS. *P* values less than 0.05 were considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics version 23.0 (IBM Co., Armonk, NY).

RESULTS
=======

Baseline characteristics and clinicopathological findings
---------------------------------------------------------

A total of 1868 patients were included between April 1996 and December 2010. Their mean age was 65 years, and 796 patients (42.6%) were female. The median follow-up duration was 46 mo (interquartile range, 22-73). During the follow-up period, 599 patients (32.1%) died. Baseline characteristics are summarized in Table [1](#T1){ref-type="table"}. All patients had data on neutrophil counts, lymphocyte counts, and platelet counts, therefore the NLR and PLR could be calculated for all patients. The mean ± SD neutrophil count, lymphocyte count, and platelet count were 5.65 ± 3.14 × 10^9^/L, 1.86 ± 0.88 × 10^9^/L, and 285.25 ± 98.11 × 10^9^/L, respectively. And the mean NLR and PLR were 4.54 ± 5.83 and 200.17 ± 168.96, respectively. On ROC analysis, the NLR and PLR were found to have the largest area under the curve (AUC = 0.569, 95%CI: 0.542-0.597, *P* \< 0.001, and AUC = 0.556, 95%CI: 0.528-0.584, *P* \< 0.001, respectively) with an optimal NLR cut-off value of 3.0 (sensitivity 51%, specificity 62%) and an optimal PLR cut-off value of 160 (sensitivity 53%, specificity 55%) for predicting OS. Patients were classified into two groups based on the optimal cut-off value of the NLR: high NLR (NLR ≥ 3.0) and low NLR (NLR \< 3.0). In addition, patients were divided into two groups according to the optimal cut-off value of the PLR: high PLR (PLR ≥ 160) and low PLR (PLR \< 160).

###### 

Baseline clinical characteristics of the enrolled patients

  **Characteristics**       **Patients (*n* = 1868)**
  ------------------------- ---------------------------
  Mean age (range), yr      65 (28-93)
  Gender                    
  Male                      1072 (57.4)
  Female                    796 (42.6)
  Location                  
  Colon                     892 (47.8)
  Rectum                    957 (51.2)
  Unknown                   19 (1.0)
  Histology                 
  Well differentiated       484 (25.9)
  Moderate differentiated   1066 (57.1)
  Poorly differentiated     139 (7.4)
  Unknown                   179 (9.6)
  Tumor stage               
  I                         281 (15.0)
  II                        551 (29.5)
  III                       667 (35.7)
  IV                        369 (19.8)
  Chemotherapy              
  No                        294 (15.8)
  Yes                       1574 (84.2)

Values are presented as mean (range) or *n* (%).

Clinicopathological findings of the patients according to NLR and PLR are summarized in Table [2](#T2){ref-type="table"}. There were statistically significant differences in T stage and peri-neural invasion according to NLR and PLR, however there were not statistically significant differences in N stage and lymphatic invasion according to NLR and PLR.

###### 

Clinicopathological findings according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio

  **Variable**           **NLR \< 3.0**   **NLR ≥ 3.0**   ***P* value**   **PLR \< 160**   **PLR ≥ 160**   ***P* value**
  ---------------------- ---------------- --------------- --------------- ---------------- --------------- ---------------
  T stage                                                 \< 0.001                                         \< 0.001
  T1                     112              39                              112              39              
  T2                     171              91                              159              102             
  T3                     668              498                             579              587             
  T4                     48               59                              41               66              
  Unknown                87               95                              82               100             
  N stage                                                 0.854                                            0.443
  N0                     589              434                             543              480             
  N1                     289              201                             257              232             
  N2                     196              138                             164              170             
  Unknown                12               9                               9                12              
  Lymphatic invasion                                      0.421                                            0.446
  Yes                    349              253                             311              291             
  No                     587              391                             524              453             
  Unknown                150              138                             138              150             
  Vascular invasion                                       0.243                                            0.011
  Yes                    193              149                             160              182             
  No                     742              496                             675              562             
  Unknown                151              137                             138              150             
  Peri-neural invasion                                    0.045                                            
  Yes                    168              142                             141              169             0.004
  No                     767              502                             693              575             
  Unknown                151              138                             139              150             

NLR: Neutrophil-to-lymphocyte-ratio; PLR: Platelet-to-lymphocyte-ratio.

Overall survival and Disease free survival according to NLR and PLR
-------------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows Kaplan-Meier curves of the OS and the DFS for patients according to NLR and PLR. The OS for patients with low NLR were better than those with high NLR (*P* \< 0.001), and the OS for patients with low PLR were also better than those with high PLR (*P* \< 0.001) (Figure [1A](#F1){ref-type="fig"}). The DFS for patients with low NLR were better than those with high NLR (*P* \< 0.001), and the DFS for patients with low PLR were also better than those with high PLR (*P* \< 0.001) (Figure [1B](#F1){ref-type="fig"}).

![Kaplan-Meier analysis shows the overall survival (A) and disease free survival (B) for patients with colorectal cancer according to neutrophil-tolymphocyte ratio and platelet-to-lymphocyte ratio.](WJG-23-505-g001){#F1}

We evaluated the long-term outcomes according to NLR and PLR based on the tumor stage. The 3-year and 5-year OS/DFS rate according to NLR and PLR based on the tumor stage are shown in Table [3](#T3){ref-type="table"}. Interestingly, the long-term outcomes according to NLR and PLR were different depending on the tumor stage (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). The OS and DFS of patients with stage I and II CRC were not significantly different according to NLR and PLR. However, the OS of patients with stage III and IV CRC were significantly different according to NLR and PLR. And the DFS of patients with stage III and IV CRC were significantly different according to NLR, but not PLR.

![Kaplan-Meier curves show the overall survival of patients with colorectal cancer according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio based on tumor stage.](WJG-23-505-g002){#F2}

###### 

Overall survival and disease free survival according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio

                          **NLR**   **PLR**           
  ----------------------- --------- --------- ------- -------
  Overall survival                                    
  Stage I                                             
  3-yr OS rate            97.0%     98.2%     99.3%   94.7%
  5-yr OS rate            92.6%     91.9%     94.8%   87.3%
  Stage II                                            
  3-yr OS rate            91.2%     89.2%     90.6%   90.1%
  5-yr OS rate            86.1%     84.0%     84.3%   86.2%
  Stage III                                           
  3-yr OS rate            79.6%     73.4%     82.1%   71.4%
  5-yr OS rate            69.3%     60.9%     69.6%   61.9%
  Stage IV                                            
  3-yr OS rate            39.8%     21.2%     33.9%   27.4%
  5-yr OS rate            34.3%     18.1%     28.6%   23.8%
  Disease free survival                               
  Stage I                                             
  3-yr DFS rate           98.3%     97.4%     98.7%   96.6%
  5-yr DFS rate           96.1%     95.6%     97.2%   93.3%
  Stage II                                            
  3-yr DFS rate           88.5%     89.3%     87.8%   89.9%
  5-yr DFS rate           84.7%     86.5%     83.5%   87.5%
  Stage III                                           
  3-yr DFS rate           79.2%     78.1%     79.8%   77.2%
  5-yr DFS rate           75.2%     68.6%     74.5%   70.5%
  Stage IV                                            
  3-yr DFS rate           42.2%     30.3%     38.5%   34.5%
  5-yr DFS rate           37.5%     26.8%     34.3%   30.4%

NLR: Neutrophil-to-lymphocyte-ratio; PLR: Platelet-to-lymphocyte-ratio; OS: Overall survival; DFS: Disease frees survival.

![Kaplan-Meier curves show the disease free survival of patients with colorectal cancer according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio based on tumor stage.](WJG-23-505-g003){#F3}

Factors affecting long-term outcomes
------------------------------------

Multivariate analysis using Cox proportional hazards regression were performed based on the tumor stage. In multivariate analysis in patients with stage I and II CRC, NLR and PLR were not significant factors affecting long-term outcomes (Table [4](#T4){ref-type="table"}). However, in patients with stage III and IV CRC, high NLR and PLR were significant prognostic factors affecting long-term outcomes (Table [5](#T5){ref-type="table"}). In patients with stage III and IV CRC, high NLR was independent factor affecting OS (HR = 1.44, 95%CI: 1.14-1.83, *P* = 0.003) and DFS (HR = 1.43, 95%CI: 1.11-1.85, *P* = 0.005), and high PLR was also independent factor affecting OS (HR = 1.35, 95%CI: 1.06-1.73, *P* = 0.017) and DFS (HR = 1.32, 95%CI: 1.02-1.69, *P* = 0.034).

###### 

Prognostic factors by multivariate Cox regression analysis (Stage I and II)

  **Predictor**                  **OS**   **DFS**                                   
  ------------------------------ -------- ----------- ---------- ------ ----------- ----------
  Age                                                                               
  \< 60 yr                       1.00                            1.00               
  ≥ 60 yr                        1.72     1.08-2.76   0.023      1.44   0.91-2.28   0.123
  Histology                                                                         
  Well/moderate differentiated   1.00                            1.00               
  Poorly differentiated          1.57     0.72-3.47   0.260      2.46   1.25-4.81   0.009
  T stage                                                                           
  T1/T2                          1.00                            1.00               
  T3/T4                          1.66     0.95-2.90   0.074      1.62   0.94-2.80   0.084
  Lymphatic invasion                                                                
  No                             1.00                            1.00               
  Yes                            0.77     0.46-1.28   0.306      1.02   0.62-1.68   0.931
  Vascular invasion                                                                 
  No                             1.00                            1.00               
  Yes                            2.36     1.46-3.84   \< 0.001   1.11   0.64-1.95   0.708
  Peri-neural invasion                                                              
  No                             1.00                            1.00               
  Yes                            2.64     1.59-4.35   \< 0.001   3.08   1.86-5.09   \< 0.001
  NLR                                                                               
  Low NLR (\< 3.0)               1.00                            1.00               
  High NLR (≥ 3.0)               1.16     0.76-1.76   0.498      1.06   0.69-1.62   0.788
  PLR                                                                               
  Low PLR (\< 160)               1.00                            1.00               
  High PLR (≥ 160)               1.07     0.71-1.62   0.744      0.98   0.64-1.49   0.908

NLR: Neutrophil-to-lymphocyte-ratio; PLR: Platelet-to-lymphocyte-ratio; OS: Overall survival; DFS: Disease free survival.

###### 

Prognostic factors by multivariate Cox regression analysis (Stage III and IV)

  **Predictor**                  **OS**   **DFS**                                   
  ------------------------------ -------- ----------- ---------- ------ ----------- ----------
  Age                                                                               
  \< 60 yr                       1.00                            1.00               
  ≥ 60 yr                        1.46     1.13-1.89   0.004      1.10   0.84-1.44   0.479
  Histology                                                                         
  Well/Moderate differentiated   1.00                            1.00               
  Poorly differentiated          1.90     1.36-2.66   \< 0.001   1.46   0.98-2.14   0.058
  T stage                                                                           
  T1/T2                          1.00                            1.00               
  T3/T4                          2.61     1.51-4.51   0.001      3.13   1.69-5.78   \< 0.001
  Lymphatic invasion                                                                
  No                             1.00                            1.00               
  Yes                            1.19     0.91-1.58   0.199      1.17   0.87-1.57   0.298
  Vascular invasion                                                                 
  No                             1.00                            1.00               
  Yes                            1.52     1.15-2.01   0.003      1.39   1.03-1.87   0.031
  Peri-neural invasion                                                              
  No                             1.00                            1.00               
  Yes                            1.45     1.10-1.91   0.008      1.56   1.16-2.08   0.003
  NLR                                                                               
  Low NLR (\< 3.0)               1.00                            1.00               
  High NLR (≥ 3.0)               1.44     1.14-1.83   0.003      1.43   1.11-1.85   0.005
  PLR                                                                               
  Low PLR (\< 160)               1.00                            1.00               
  High PLR (≥ 160)               1.35     1.06-1.73   0.017      1.32   1.02-1.69   0.034

NLR: Neutrophil-to-lymphocyte-ratio; PLR: Platelet-to-lymphocyte-ratio; OS: Overall survival; DFS: Disease free survival.

DISCUSSION
==========

This study showed that stage III and IV CRC patients with high NLR or high PLR at initial diagnosis had poor prognosis. According to the results of this study, high NLR and high PLR are useful independent prognostic factors to predict poor long-term outcomes in patients with stage III and IV CRC.

The mechanism by which high NLR or high PLR affects poor long-term outcomes in patients with cancer is not clearly. Recent studies suggested that inflammation and cancer are closely connected by the intrinsic and extrinsic pathways\[[@B11],[@B12]\]. The intrinsic pathway is activated by genetic alterations resulting in neoplasia, whereas inflammatory conditions increase the risk of developing cancer in the extrinsic pathway. The two pathways result in the activation of transcription factors in tumor cells including NF-kB, STAT3, and hypoxia-inducible factor 1α, and these transcription factors produce inflammatory mediators including cytokines and chemokines\[[@B11]\]. By these processes, the inflammatory response contributes to the pathogenesis and progression of cancer. The relationship between chronic inflammation and CRC has been established by the observations showing the increased risk of CRC in patients with inflammatory bowel disease\[[@B27]\]. Increased NLR or PLR indicates a relative reduction in lymphocytes and lymphocyte-mediated immune response, which plays a crucial role in cytotoxic cell death. And elevated neutrophils and platelets can cause the synthesis of chemokines, growth factors to promote angiogenesis and tumor progression\[[@B20]\].

Several studies have reported that some laboratory markers including C-reactive protein and modified Glasgow prognostic score have prognostic value in the cancer population\[[@B28]-[@B30]\]. However, these laboratory markers are not routinely examined as part of the pretreatment assessment of patients with CRC in most hospitals. Whereas, since neutrophil count, platelet count, and lymphocyte count are routinely evaluated, NLR and PLR could be inexpensive prognostic markers which can easily be assessed in clinical practice.

There has been rapidly growing interest in the association between NLR and long-term outcomes in patients with CRC\[[@B16],[@B23],[@B24],[@B26],[@B31]\]. Recently, two meta-analyses showed significant evidence to support the association between high NLR and poor prognosis in patients with CRC\[[@B25],[@B32]\]. In this study, we aimed to identify and strengthen the role of NLR and PLR in patients with CRC, therefore we performed the analysis with a large number of CRC patients to determine if these ratios could be useful for predicting long-term outcomes. We identified that patients with low NLR and low PLR showed longer overall survival and disease free survival than those with high NLR and high PLR (Figure [1](#F1){ref-type="fig"}). Previous studies reported that preoperative NLR may be an independent prognostic marker to predict long-term outcomes in stage II and III CRC\[[@B23],[@B33]-[@B35]\], and also an important predictive marker in stage IV CRC\[[@B36]-[@B38]\]. In our study, we demonstrated that NLR and PLR have predictive values for OS and DFS in patients with stage III and IV CRC. High NLR and high PLR were independent factors affecting OS and DFS in patients with stage III and IV CRC (Table [5](#T5){ref-type="table"}). These findings suggest that stage III and IV CRC patients who have high NLR and high PLR should be more carefully managed when establishing a treatment strategy. Whereas, NLR and PLR were not prognostic factors in patients with stage I and II CRC (Table [4](#T4){ref-type="table"}). These findings suggest that the assessment of NLR and PLR should be interpreted differently depending on the tumor stage of CRC.

Several studies have proposed various cut-off values of NLR and PLR for OS (for instance, 3 to 5 as a cut-off value of NLR and 150 to 225 as a cut-off value of PLR)\[[@B24],[@B32],[@B35],[@B38]-[@B40]\]. In this study, the cut-off value of NLR was 3.0 (sensitivity 51%, specificity 62%) and the cut-off value of PLR was 160 (sensitivity 53%, specificity 55%). Although the sensitivity and specificity of the cut-off values of NLR and PLR in our results were not high, these values could be relatively reliable due to the large number of patients included in our study.

This study has some limitations. First, this study was retrospectively performed in a single center. Therefore, we could not avoid selection bias when collecting information on patients with CRC. However, we attempted to minimize any bias by repeatedly reviewing the medical records. Second, the NLR and PLR were assessed by single measurements at the time of admission for the initial diagnosis. It would be interesting to examine changes in NLR and PLR during the follow-up period in CRC patients to determine their usefulness as surveillance markers.

In conclusion, our study showed that high NLR and high PLR are useful prognostic factors to predict poor long-term outcomes in patients with stage III and IV CRC. Based on the results of this study, we suggest that initial assessment of NLR and PLR in newly diagnosed stage III and IV CRC patients is important for predicting long-term outcomes.

COMMENTS
========

Background
----------

Identification of prognostic markers is an important step for assessing clinical outcome in colorectal cancer (CRC) treatment. Recently, a large number of studies have suggested useful biomarkers for predicting clinical outcomes in CRC, however high costs and lack of standardization limit their application in routine clinical practice. Inflammatory response has a crucial role in the pathogenesis and progression of cancer. Among the various inflammatory markers, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been shown to influence clinical outcomes in various cancers. NLR and PLR can be easily calculated as the neutrophil count or platelet count divided by the lymphocyte count. In this study, we aimed to identify the prognostic value of the NLR and PLR in patients with CRC.

Research frontiers
------------------

This study presents that high NLR (≥ 3.0) and high PLR (≥ 160) are useful prognostic factors to predict poor long-term outcomes in patients with stage III and IV CRC.

Innovations and breakthroughs
-----------------------------

In this study, a total of 1868 patients were included. The authors used ROC curves to assess optimal cut-off values of the NLR and PLR, and evaluated the roles of the NLR and PLR using Kaplan-Meier curves and Cox regression models in predicting the long-term outcomes in patients with CRC.

Applications
------------

Initial assessment of NLR and PLR in newly diagnosed stage III and IV CRC patients can be helpful to predict long-term outcomes.

Terminology
-----------

NLR: calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. PLR: calculated by dividing the absolute platelet count by the absolute lymphocyte count.

Peer-review
-----------

This is an interesting retrospective study including a large cohort of CRC patients. Some data are missing and should be supplemented by the authors.
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